Skip to main content
Baricitinib Lilly 2 and 4 mg Film-Coated Tablets Patient Alert Card
Patient Alert Card containing important safety information for patients.
Back to top
Risk Minimisation Materials
Search by company, common medicine name, or title of Risk Minimisation Material
Baricitinib
Eli Lilly and Company Limited
Baricitinib Lilly 2 mg and 4 mg Film-Coated Tablets guidance for Healthcare Professionals for Atopic Dermatitis and Alopecia Areata
For Healthcare Professionals
Important risk minimisation information for healthcare professionals prescribing Baricitinib Lilly (baricitinib)
Bavencio
Merck
Bavencio 20 mg/ml concentrate for solution for infusion (avelumab) – Patient Alert Card
Proposed changes are:
• removal of the patient information brochure from the educational material, following
the PRAC assessment report PSUSA/00010635/202303
• removal of the black symbol and explanatory statements for medicinal products subject
to additional monitoring
• aligned terminology with the RMP for the term "immune-related" versus "immunemediated.
• additional editorial changes introduced by MAH.
Please find attached latest approved Patient alert card with marked changes and in clean
version.
Bekemv
Amgen Ltd
BEKEMV Patient Safety Card
Important Safety Information for Patients Receiving BEKEMV and showing this card to any doctor involved in your care.
BEKEMV Patient/Parent Information Brochure
This guide is for adult patients and parents/legal guardians of a child (above 2 years) who has been prescribed eculizumab. The guide provides you with important safety information that you must be aware of.
BEKEMV Physician Guide
For Healthcare Professionals
he aim of this brochure is to educate and/or remind healthcare professionals about the selected prevention measures, detection, careful monitoring and/or proper management of selected safety concerns associated with eculizumab.
BEKEMV Vaccination Certificate
For Healthcare Professionals
Drug distribution will only be possible after written
confirmation that the patient received or will receive
meningococcal vaccination and/or antibiotic
prophylaxis from the healthcare providers
Belkyra
AbbVie Ltd
Injector's Guide For The Safe Use Of Belkyra
For Healthcare Professionals
This guide provides important information on the safe and effective use of BELKYRA (deoxycholic acid) in order to minimise the risk of injection site nerve injury and associated motor neuropraxia, injection site skin ulceration and necrosis.
The guide contains:
1. Information on how to report suspected adverse drug reactions
2. Figures to show anatomical structures of the neck/ key anatomic landmarks of the cervicomental region/ submental fulness scale
3. Checklist for the administration of Belkyra
4. Procedure checklist
Benepali
Biogen Biosimilars
Benilexa
Gedeon Richter (UK) Ltd
Benilexa One Handed Healthcare Professional Guide
For Healthcare Professionals
Updated HCP guide to minimise the risk of application errors due to confusion of different types of IUS and to reduce the risk of ectopic pregnancies.
Beovu
Novartis Pharmaceuticals UK Ltd
Beovu (Brolucizumab) - Patient Guide to Therapy - for patients
This guide contains important information about Beovu (Brolucizumab) why its been prescribed, side effects and their potential risks.
Beovu (Brolucizumab) - Patient Guide to Therapy - for patients with visual impairment due to DMO
This guide contains important information about Beovu (Brolucizumab) why its been prescribed, side effects and their potential risks. For patients with visual impairment due to DMO.
Bimizza
Morningside Healthcare Ltd
Checklist for Prescribers - Bimizza 150 microgram/20 microgram Tablets
For Healthcare Professionals
Please use this checklist in conjunction with the Summary of Product Characteristics during combined hormonal contraceptive (CHC) consultations.
•Thromboembolism (e.g. deep vein thrombosis, pulmonary embolism, heart attack and stroke) is a rare but important risk with use of a CHC.
Important Information for Women Leaflet - Bimizza 150 microgram/20 microgram Tablets
All women should understand: the small risk of blood clots with combined hormonal contraceptives; what other conditions increase the risk of a blood clot; the signs and symptoms of a blood clot; and when you need to tell a healthcare professional that you are using a combined hormonal contraceptive. Although the risk is small, blood clots can be serious. This information will help you minimise your risk.
Patient Alert Card - Bimizza 150 microgram/20 microgram Tablets
IMPORTANT INFORMATION FOR WOMEN ABOUT RISK OF BLOOD CLOTS WITH COMBINED HORMONAL CONTRACEPTIVES
Blenrep
GlaxoSmithKline UK
Cover Letter – Risk Minimisation Materials
For Healthcare Professionals
This letter outlines the risk minimisation materials developed to explain the corneal adverse reactions that may occur with belantamab mafodotin treatment and to provide monitoring and management guidance.
Eye Care Evaluation guide for Physicians and Eye Care Professionals
For Healthcare Professionals
This guide provides instructions to facilitate communication between prescribers and eye care professionals for corneal monitoring and management of patients receiving treatment with belantamab mafodotin.
Important Information for Eye Care Professionals: Corneal Adverse Reactions
For Healthcare Professionals
This guide is to provide eye care professionals with an overview of corneal adverse reactions that may occur with belantamab mafodotin treatment and to explain the important role of eye care professionals in the monitoring and management of patients receiving belantamab mafodotin
Important Information for Physicians: Management of Corneal Adverse Reactions
For Healthcare Professionals
This guide is to provide healthcare professionals with an overview of corneal adverse reactions that may occur with belantamab mafodotin treatment and guidance regarding supportive care and dose modifications to manage corneal adverse reactions
Patient guide: Important information on Understanding the Vision and Eye Changes with treatment
For Healthcare Professionals
This guide for patients provides an overview of the vision and eye changes that may occur with belantamab mafodotin treatment.
Patient Wallet Card
This patient wallet card should be given to all patients to record their care team contact details. Patients should carry this card with them at all times.
Pharmacy Eye Drop wallet Card
This eye drop wallet card should be given to all patients to present to their pharmacist who will help provide preservative-free artificial tears eye drops. Patients should carry this card with them at all times
Blincyto
Amgen Ltd
BLINCYTO Guide for Nurses
For Healthcare Professionals
This educational brochure contains important information regarding the administration of BLINCYTO and the risks of
medication errors and neurologic events. This educational material is essential to ensure the safe and effective use of
the product and appropriate management of the important selected risks and therefore it is advised to be read carefully
before administering the medicinal product.To request a copy of the brochure, please contact Amgen Medical Information on +44 (0) 1223 436441
BLINCYTO Guide for Patients and Caregivers
This educational brochure contains important information you should know before receiving BLINCYTO. This educational material is essential to ensure the safe and effective use of the drug and appropriate management of the important selected risks. Please read it carefully before taking the medicinal product.
To request a copy of this guide, please contact Amgen Medical Information on +44 (0) 1223 436441
BLINCYTO Guide for Pharmacists
For Healthcare Professionals
This educational brochure contains important information regarding the reconstitution and preparation procedures
for blinatumomab. To ensure the safe and effective use of the medicinal product and appropriate management of the
important selected risks, please carefully read this material before reconstituting and preparing of the medicinal product.To request a copy of the brochure, please contact Amgen Medical Information on +44 (0) 1223 436441
BLINCYTO Guide for Physicians
For Healthcare Professionals
This educational brochure contains important information regarding the administration of BLINCYTO and the risks of
medication errors and neurologic events. This educational material is essential to ensure the safe and effective use of
the product and appropriate management of the important selected risks and therefore it is advised to be read carefully
before prescribing and administering the medicinal product.To request a copy of the brochure, please contact Amgen Medical Information on +44 (0) 1223 436441
BLINCYTO Patient Alert Card
This BLINCYTO patient alert card contains a warning message for HCPs that the patient is using BLINCYTO, includes contact details of the BLINCYTO prescriber and treatment start date, and information on the importance of reporting ADRs.
To request a copy of the patient card, please contact Amgen Medical Information on +44 (0) 1223 436441
Bosentan
Aurobindo Pharma - Milpharm Ltd.
Bosentan Milpharm - Patient Alert Card
Important Safety Alerts for Patients taking Bosentan Milpharm
Cipla EU Ltd
Dr. Reddy's Laboratories (UK) Ltd
Bosentan Dr. Reddy's 62.5 mg & 125 mg Film-coated Tablets Patient leaflet Important Safety Information
Important Safety Alerts for Patients Taking Dr. Reddy's Bosentan 62.5 mg & 125 mg Film-coated Tablets
Mylan
Zentiva
Bosentan- Patient Alert Guide
This card contains important information about bosentan. Please read this card carefully before starting your treatment with bosentan.
For hard copies please contact our medical information department on 0800 090 2408 or email [email protected]
Braltus
Teva UK Limited
Risk Minimisation Information on Potential Risk of Medication Errors - Guide for HCPs
For Healthcare Professionals
This educational guide is provided to highlight and minimise the potential risk of prescribing and administration errors (medication errors) due to the differences between Braltus
(tiotropium bromide) and the originator product Spiriva® HandiHaler® (tiotropium bromide) with respect to the pre-metered dose.
Brancico
Zentiva
Brancico XL 50mg, 150mg, 200mg, 300mg and 400mg prolonged-release tablets Educational material for health care professionals
For Healthcare Professionals
Educational material for health care professionals Brancico XL 50mg, 150mg, 200mg, 300mg and 400mg prolonged-release tablets For hard copies please contact our medical information department at 0800 090 2408 or email [email protected]
Brinavess
ADVANZ Pharma
Appropriate use of Brinavess
For Healthcare Professionals
Appropriate use of Brinavess (vernakalant hydrochloride)
concentrate for solution for infusion
Brinavess Pre-infusion Checklist
For Healthcare Professionals
Prior to administration the prescriber is asked to determine eligibility of the patient through use of the supplied checklist. The
checklist should be placed on the infusion container to be read by the healthcare professional who will administer BRINAVESS.
Bronchitol
Pharmaxis Europe Limited
Bronchitol Healthcare Professional Leaflet
For Healthcare Professionals
Bronchitol Healthcare Professional Leaflet
Byooviz
Samsung Bioepis UK Limited
Byooviz Patient Booklet – Treatment of AMD
This booklet is for patients using Byooviz for the treatment of nAMD. The booklet forms part of the patient information pack (educational materials). The booklet provides an overview on how Byooviz works, how treatment is administered and what to expect, the key signs and symptoms of potential adverse reactions and when to seek urgent attention from the physician, ensuring rapid identification and treatment of these events.
Byooviz Patient Booklet – Treatment of CNV
This booklet is for patients using Byooviz for the treatment of CNV. The booklet forms part of the patient information pack (educational materials). The booklet provides an overview on how Byooviz works, how treatment is administered and what to expect, the key signs and symptoms of potential adverse reactions and when to seek urgent attention from the physician, ensuring rapid identification and treatment of these events.
Byooviz Patient Booklet – Treatment of PDR-DMO
This booklet is for patients using Byooviz for the treatment of PDR and DMO. The booklet forms part of the patient information pack (educational materials). The booklet provides an overview on how Byooviz works, how treatment is administered and what to expect, the key signs and symptoms of potential adverse reactions and when to seek urgent attention from the physician, ensuring rapid identification and treatment of these events.
Byooviz Patient Booklet – Treatment of RVO
This booklet is for patients using Byooviz for the treatment of RVO. The booklet forms part of the patient information pack (educational materials). The booklet provides an overview on how Byooviz works, how treatment is administered and what to expect, the key signs and symptoms of potential adverse reactions and when to seek urgent attention from the physician, ensuring rapid identification and treatment of these events.
You are trying to reach document intended for healthcare professionals only.
Are you a healthcare professional?
